SHL's SmartHeart portable 12-lead ECG technology participated in the U.S. Army's Project Convergence-Capstone 4 Experiment (PC-C4) and demonstrated superior reliability, ease of use, and effectiveness even in extreme scenarios.
Tel Aviv, Israel, Zurich, New York, April 8, 2024–(BUSINESS WIRE)–SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) (“SHL” or “company) A leading provider and developer of advanced personal telehealth solutions, the company has demonstrated remarkable innovation and operational excellence, with SmartHeart®, its portable 12-lead ECG technology, demonstrating unparalleled capabilities. We are happy to share that we have demonstrated and successfully participated in Project Convergence. Capstone 4 (PC-C4) is the largest two-phase “hands-on” experiment to date, and the Project Convergence of Perpetual Experiment. Contains persistent goals and learning requests that evolved from the campaign. One of the key events during the experiment was a comprehensive, multi-day Army medical experiment at the National Training Center at Fort Irwin in the Mojave Desert, surrounded by the rugged terrain of California's Tyfort Mountains.
Designed to revolutionize emergency cardiovascular assessment in non-traditional settings, SmartHeart® provides critical support across a variety of care roles during experimentation, delivering fast and accurate results at different levels of trauma care. ensure accurate assessment of cardiac status. SmartHeart® technology has been used in rugged desert conditions by a diverse group of medical clinicians, including nurses, physicians, and physicians, demonstrating reliability, ease of use, and effectiveness in extreme conditions.
PC-C4, a multinational collaborative experiment hosted by the U.S. Army at multiple locations in February and March, allowed military medicine to explore and integrate the latest innovations in field settings. SmartHeart's participation in this prestigious experiment confirms the growing recognition of his SHL's portable ECG technology as a game changer in the fast-paced and demanding military medical field.
Jason Bottiglieri, general manager of SHL Telemedicine USA, emphasized the importance of this accomplishment, saying, “The Army's request to join SHL and SmartHeart's exemplary performance on PC-C4 has led to a Confirms the critical role of our technology in addressing the continuum of military medical needs, from initial non-combat assessment to trauma response and advanced interventions for intensive and continuous care. SmartHeart's robust performance in experimental, challenging operational and environmental conditions promises to transform the way cardiac status is assessed and managed in field operations. This ultimately leads to better outcomes for those working on the front lines.”
About SHL Telemedicine
SHL Telemedicine is engaged in the development and marketing of personal telemedicine systems and the provision of medical call center services with a focus on cardiovascular and related diseases to end users and the medical community. SHL Telemedicine utilizes telephone and Internet communication technologies to provide services and personal telemedicine devices to its subscribers. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, stock number: 1128957) and the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website www.shl-telemedicine.com.
Forward-looking statements
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Please note that it may vary. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240407836555/ja/
contact address
Fabienne Farner, IRF, Tel: +41 43 244 81 42, farner@irf-reputation.ch
